Browse EX-10 agreements

Manulife Private Credit Fund

SUBADVISORY AGREEMENT

This AGREEMENT (this “Agreement”) is made as of this 1st day of March, 2026 (the “Effective Date”), by and between Manulife Investment Management Private Markets (US) LLC, a Delaware limited liability company (the “Adviser”), and Comvest Credit Advisors LLC, a Delaware limited liability company (the “Subadviser”). In consideration of the mutual covenants contained herein, the parties agree as follows:

1.	APPOINTMENT OF SUBADVISER

The Subadviser undertakes to act as the investment subadviser to and, subject to the supervision of the Board of Trustees (the “Board”or the “Trustees”) of Manulife Private Credit Fund (the “Portfolio”) and the terms of this Agreement, to manage the investment and reinvestment of the assets of the Portfolio. The Subadviser shallbe an independent contractor and will have no authority to act for or represent the Portfolio or Adviser in any way or otherwise be deemed an agent unless expressly authorized in this Agreement or in another writing by the Portfolio and/or Adviser, as applicable.

2.	SERVICES TO BE RENDERED BY THE SUBADVISER TO THE PORTFOLIO

…

---

Exhibit 10.1

FIRST BANCORP

2026 OMNIBUS INCENTIVE PLAN

Section I

PURPOSE

The purpose of the First BanCorp 2026 Omnibus Incentive Plan, as it may be amended from time to time (the “Plan”), is to promote the interests of the Corporation and its stockholders by delivering long term incentive compensation benefits to the Corporation’s and its Affiliates’ employees and directors, who are expected to contribute significantly to the success of the Corporation and its Affiliates.  These benefits provide a proprietary interest in the continued growth and success of the Corporation through the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The Plan is also intended to encourage recipients to remain in the employ or service of the Corporation and its Affiliates and to assist the Board and management in the attraction and recruitment of qualified service providers to serve the Corporation and/or its Affiliates. The Plan is intended to comply with Section 1040.08 of the P.R. Code, with respect to the Puerto Rico directors and employees participating thereunder, and Sections 409A and 422 of the U.S. Code, with respect to the U.S. employees participating in the Plan. The Plan shall be effective on the Effective Date.

…

AMENDED AND RESTATED LICENSE AGREEMENT

THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made and entered into as of April 30, 2026 (“Effective Date”), by and between SEKISUI HOUSE, LTD., a Japanese public company with its principal place of business at 1-1-88, Oyodonaka, Kita-ku, Osaka, 531-0076, JAPAN (“Licensor”), and Sekisui House U.S., Inc., a Delaware corporation with its principal place of business at 4350 South Monaco Drive, Denver, CO 80237, USA (“Licensee”).

BACKGROUND

WHEREAS, Licensor indirectly owns 100% of the equity interests in Licensee;

WHEREAS, Licensee is engaged, both directly and indirectly through subsidiaries, in the business of conducting certain homebuilding activities in the USA;

WHEREAS, Licensee (a) owns 100% of the equity interests in entities that are involved in certain homebuilding activities in the USA and (b) may in the future own, directly or indirectly, equity interests in other entities that may be formed to carry out certain homebuilding activities in the USA, in each case involving the products or intellectual property of Licensor (the entities contemplated in (a) and (b), each, a “Sublicensee”)

WHEREAS, Licensor desires to grant a license to Licensee under certain Intellectual Property Rights owned or Licensable by Licensor and Licensee desires to obtain such right for the purpose of conducting its Business in the Territory pursuant to the terms and conditions set forth in this Agreement;

…

FIRST AMENDMENT TO THE

SEKISUI HOUSE U.S., INC.

(formerly known as M.D.C. Holdings, Inc.)

LONG TERM INCENTIVE PLAN

This First Amendment (the “First Amendment”) amends the M.D.C. Holdings, Inc. Long Term Incentive Plan, approved January 30, 2025, with an Effective Date of January 1, 2025 (the “Plan”). All capitalized terms not defined herein shall have the meaning defined in the Plan.

RECITALS

M.D.C. Holdings, Inc. changed its legal name to Sekisui House U.S., Inc., on or about September 4, 2025.

Section 8(d) of the Plan permits the Plan to be amended as provided therein. The Company has determined that it is beneficial to amend the Plan to be effective for all Long Term Incentive Awards that are granted on or after January 1, 2026.

AMENDMENT

The Plan is hereby amended as follows:

1.The name of the Plan is the “Sekisui House U.S., Inc. Long Term Incentive Plan.”

2.All references to “M.D.C. Holdings, Inc.” in the Plan are hereby replaced with “Sekisui House U.S., Inc.”

3.Section 5(b) of the Plan document is hereby amended and fully replaced with the following:

…

Employee Form Exhibit 10.2

DAMORA THERAPEUTICS, INC.

2026 EQUITY INCENTIVE PLAN

GRANT NOTICE FOR STOCK OPTIONS

FOR GOOD AND VALUABLE CONSIDERATION, Damora Therapeutics, Inc. (the “Company”), hereby grants to Participant named below an option (the “Option”) to purchase any part or all of the number of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and upon the terms and subject to the conditions set forth in this Grant Notice, the Damora Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”), and the Standard Terms and Conditions (the “Standard Terms and Conditions”) promulgated under such Plan and attached hereto as Exhibit A. This Option is granted pursuant to the Plan and is subject to and qualified in its entirety by the Standard Terms and Conditions. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.

…

April 13, 2026

Jonathan Siegler

Dear Mr. Siegler,

DIRECTOR SERVICES APPOINTMENT AS A NON-EXECUTIVE DIRECTOR OF 5E ADVANCED MATERIALS, INC.

We are pleased and welcome your acceptance to be appointed as a Non-Executive Director (“NED”) of 5E Advanced Materials, Inc. (the “Company”), a company incorporated under the laws of the State of Delaware.

The following letter seeks to illustrate the context of your appointment by the Company, and the terms and conditions of such appointment, as set out herewith. It is agreed that on acceptance of this offer, this letter will constitute a contract for services and not a contract of employment.

For purposes of independence, this letter will supersede all previous or contemporaneous oral or written appointments, contracts or agreements, if applicable, entered into between yourself and the Company (or its affiliated subsidiaries). By signing this letter and therefore accepting the appointment as stated, you agree to terminate all other previous appointments with the Company, its subsidiaries and affiliates thereof commencing effective April 13, 2026 (“Effective Date”), on the following terms and conditions:

1. Appointment

(a)

You shall agree to be appointed by the Nominating and Corporate Governance Committee of the Board of Directors of the Company (the “Board”) to act as a NED of the Company.

(b)

You shall agree to be appointed by the Board as a member and/or chair of sub-committees as may be determined by the Board:

…

RECIPROCAL LOAN AGREEMENT

This RECIPROCAL LOAN AGREEMENT (this “Agreement”), dated as of April 1, 2026, between Voya Retirement Insurance and Annuity Company, a Connecticut life insurance company (“VRIAC” or “Company”), located at One Orange Way, Windsor, Connecticut 06095 and Voya Financial, Inc., a Delaware corporation (“Voya Financial” or “Company”), located at 200 Park Avenue, New York, New York 10166 (collectively referred to as the "Companies").

WITNESSETH:

WHEREAS, each of the Companies may have, from time to time, a need to borrow funds on a revolving basis; and

WHEREAS, each of the Companies may have, from time to time, excess cash available to lend to the other on a revolving basis; and

WHEREAS, the Companies are affiliated entities and as such are willing to extend financing to, and borrow from each other as provided herein; and

WHEREAS, each of the Companies desires to enter into this Agreement providing for, among other things, the making of such Loans by and among each other;

NOW, THEREFORE, for and in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Companies agree as follows:

ARTICLE 1

DEFINITIONS

Section 1.1.    Defined Terms. For purposes of this Agreement:

“Agreement” shall have the meaning set forth in the preamble hereto.

“Authorized Person” shall mean the CFO, Treasurer, Assistant Treasurer, Treasury Officer, or Treasury Manager of the Borrowing Company, or a person so designated.

…

SOLID BIOSCIENCES INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”).

Director Compensation

Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company’s affairs. We also seek to align the interests of our directors and our stockholders, and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.

Cash Compensation

The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of each committee of the Board will be as follows:

	Member Annual Fee	Chairperson Incremental Annual Fee
Board of Directors	$40,000	$35,000
Audit Committee	$10,000	$20,000
Clinical Committee	$7,500	$7,500
Compensation Committee	$6,000	$12,000
Nominating and Corporate Governance Committee	$5,000	$10,000

…

HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT

and

AMBIQ MICRO SINGAPORE PRIVATE LTD.

Lease for

10 KALLANG AVENUE

#14-10 TO #14-13 APERIA

SINGAPORE 339510

---

SCHEDULE 1 DETAILS OF LEASE

Item 1:	Landlord (we, us, our)	:	HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT
Item 2:	Tenant (you, your)	:	AMBIQ MICRO SINGAPORE PRIVATE LTD.
Item 3:	Premises
	(a) Unit numbers	:	#14-10 to #14-13 Aperia
	(b) Building	:	10 Kallang Avenue Aperia Singapore 339510
	(c) Boundary	:	(for identification only) edged in red in the attached plan (or plans), marked as schedule 5
Item 4:	Floor Area	:
	Unit numbers #14-10 to #14-13 Aperia Total Floor Area		Floor Area (square metre) 875.45 875.45
Item 5:	Possession Date	:	15 January 2026
Item 6:	Start Date	:	15 March 2026
Item 7:	Term	:	36 months & 17 days beginning from the Start Date
Item 8:	Permitted Use	:	Research & development and design of semiconductor solutions and as an ancillary office only
Item 9:	Rent	:

(a) The Gross Rent, Net Rent and Service Charge are as follows.

…

EXCLUSIVE LICENSE AGREEMENT

This  Exclusive License Agreement (this “Agreement”) is effective as of March 15, 2026 (the “Effective Date”) and made and entered into on May 8, 2026 (the “Execution Date”), by and between Impetis Biosciences Limited, a company incorporated in India, having a place of business at address of 6th Floor, Wing E, Times Square, Marol, Andheri-Kurla Road, Gamdevi, Andheri-East, Mumbai, 400059, Maharashtra, India (“Licensor”), and Vyome Holdings, Inc., a Delaware corporation having its principal office at Harvard Square One Mifflin Place, Suite 400, Cambridge, MA 02138 (the “Licensee” and together, with the Licensor, the “Parties” and each a “Party”).

Recitals

WHEREAS, Licensor is in the business of progressing its high-value assets through collaborations and partnerships in order to transform the lives of patients suffering from diseases that have no or limited therapeutic choices;

WHEREAS, Licensor developed certain proprietary compounds for the treatment of various immuno-inflammatory and other conditions, disclosed or included in, or covered by any of the Licensed Patents (as defined below);

WHEREAS, Licensee is a clinical stage drug development company focused on developing and commercializing of drugs for immune-inflammatory conditions and rare diseases; and

WHEREAS, Licensor desires to grant to Licensee, and Licensee desires to obtain from Licensor, an exclusive license to the Licensed Compound(s) (as defined below) under Licensor Intellectual Property, all on the terms and conditions set out below.

…

Exhibit 10.6

AMENDMENT NO. 2 TO CONSULTING AGREEMENT

This AMENDMENT NO.2 (“Amendment No. 2”) to the CONSULTING AGREEMENT dated April 11, 2024 and amended November 21, 2024 (the “Agreement”) between OPUS GENETICS INC., a Delaware corporation having its principal place of business at 8 Davis Drive, Durham, NC, 27713 (the “Company”), and JAY S. PEPOSE MD, whose address is 1125 Templeton Place, Chesterfield, MO 63017 (“Consultant”) is made as of April 10, 2026 (the “Effective Date”).

I.The term of the Agreement shall be extended to May 11, 2026.

II.All other terms of the Agreement remain in effect without change.

Having understood and agreed to the foregoing, the Company and Consultant have signed this Amendment No.2 and the same shall be effective as of the Effective Date.

IN WITNESS WHEREOF, the parties have, by duly authorized persons, executed this Agreement as of the Effective Date.

JAY PEPOSE, MD									OPUS GENETICS, INC.
By:			/s/ Jay S. Pepose, M.D.						By:			/s/ Sally Tucker
			Jay Pepose, MD									Sally Tucker, PhD
			Chief Medical Advisor									CMO

Exhibit 10.5

Executed Version

WAIVER AND OMNIBUS AMENDMENT OF

NOTE PURCHASE AGREEMENT

AND

STOCK PURCHASE AND CONVERSION AGREEMENT

April 13, 2026

This Waiver and Omnibus Amendment (this “Amendment”), dated as of the date first set forth above, is entered into by and among Opus Genetics, Inc., a Delaware corporation (the “Company”), OpusTX, LLC, a Delaware limited liability company (the “Guarantor” and, together with the Company, the “Obligors” and each, an “Obligor”), the Persons listed on the signature pages hereof under the heading “PURCHASERS” (each a “Purchaser” and, collectively, the “Purchasers”), and OPCM SA LLC, a Delaware limited liability company (“Purchaser Agent”).

Reference is hereby made to (i) the Note Purchase Agreement, dated as of April 2, 2026 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Note Purchase Agreement”), by and among the Obligors, the Purchasers from time to time party thereto and the Purchaser Agent, and (ii) the Stock Purchase and Conversion Agreement, dated as of April 2, 2026 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Stock Purchase Agreement”), by and among the Company and the Purchasers. Capitalized terms not otherwise defined in this Amendment shall have the meanings set forth in the Note Purchase Agreement or Stock Purchase Agreement, as applicable. The Obligors, Purchasers and Purchaser Agent are sometimes referred to herein individually as a

…